Nuvectis Pharma annual return on equity
2022
2023
2024
2025
Nuvectis Pharma Return on Equity (ROE) Growth & History (NVCT)
Nuvectis Pharma's return on equity was −188.03% for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −188.03% | −14.62 pp |
| 2024 | 2024-12-31 | −173.41% | −4.90 pp |
| 2023 | 2023-12-31 | −168.51% | +1020.22 pp |
| 2022 | 2022-12-31 | −1,188.73% | — |
Nuvectis Pharma quarterly return on equity
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −60.25% | −26.76 pp |
| Q1 2026 | 2026-03-31 | −37.08% | −2.31 pp |
| Q4 2025 | 2025-12-31 | −34.48% | +25.87 pp |
| Q3 2025 | 2025-09-30 | −36.51% | −1.19 pp |
| Q2 2025 | 2025-06-30 | −33.49% | −0.13 pp |
| Q1 2025 | 2025-03-31 | −34.77% | −2.96 pp |
| Q4 2024 | 2024-12-31 | −60.36% | −14.51 pp |
| Q3 2024 | 2024-09-30 | −35.32% | −3.54 pp |
| Q2 2024 | 2024-06-30 | −33.36% | +1.66 pp |
| Q1 2024 | 2024-03-31 | −31.81% | −1.25 pp |
| Q4 2023 | 2023-12-31 | −45.85% | −7.13 pp |
| Q3 2023 | 2023-09-30 | −31.77% | +5.10 pp |
| Q2 2023 | 2023-06-30 | −35.01% | −7.62 pp |
| Q1 2023 | 2023-03-31 | −30.57% | +135.19 pp |
| Q4 2022 | 2022-12-31 | −38.71% | — |
| Q3 2022 | 2022-09-30 | −36.88% | — |
| Q2 2022 | 2022-06-30 | −27.39% | — |
| Q1 2022 | 2022-03-31 | −165.76% | — |
Nuvectis Pharma return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Nuvectis Pharma's return on equity increased from −1,188.73% to −188.03%, a change of +1000.70 percentage points. The latest reported quarter, Q2 2026, shows −60.25%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗